Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 4, Issue 10, Pages 1333-1340Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.4.10.1333
Keywords
I-131; pilocarpine; radiation therapy; Sjogren's syndrome; xerostomia
Ask authors/readers for more resources
Background: Xerostomia is the feeling of dryness in the mouth, usually owing to hypofunctioning of the salivary glands. Causes of xerostomia include medications, the effects of radiation therapy on the salivary glands during the treatment of head and neck cancer or thyroid cancer, and autoimmune diseases such as Sjogren's syndrome. The primary treatment to reduce xerostomia is oral pilocarpine. Objective: This review discusses the randomized trials available on the efficacy and tolerability of oral pilocarpine for the treatment of xerostomia. Methods: The randomized trials of pilocarpine for xerostomia available in the medical literature are reviewed. Results/conclusion: Pilocarpine has some efficacy in the treatment of xerostomia from radiation therapy, graft-versus-host disease and Sjogren's syndrome. It has limited activity for the prevention of xerostomia during radiation therapy. it may have increased efficacy in combination with newer forms of radiation therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available